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Background: The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) causes symptoms similar to Severe
Acute Respiratory Syndrome Coronavirus (SARS-CoV), yet involving an additional component of acute renal failure
(ARF) according to several published case reports. Impairment of the kidney is not typically seen in Coronavirus
infections. The role of kidney infection in MERS is not understood.
Findings: A systematic review of communicated and peer-reviewed case reports revealed differences in descriptions
of kidney involvement in MERS versus SARS patients. In particular, ARF in MERS patients occurred considerably earlier
after a median time to onset of 11 days (SD ±2,0 days) as opposed to 20 days for SARS, according to the literature.
In-situ histological staining of the respective cellular receptors for MERS- and SARS-Coronavirus showed highly similar
staining patterns with a focus of a receptor-specific signal in kidney epithelial cells. Comparative infection experiments
with SARS- and MERS-CoV in primary human kidney cells versus primary human bronchial epithelial cells showed
cytopathogenic infection only in kidney cells, and only if infected with MERS-CoV. Kidney epithelial cells produced
almost 1000-fold more infectious MERS-CoV progeny than bronchial epithelial cells, while only a small difference was
seen between cell types when infected with SARS-CoV.
Conclusion: Epidemiological studies should analyze kidney impairment and its characteristics in MERS-CoV. Virus
replication in the kidney with potential shedding in urine might constitute a way of transmission, and could explain
untraceable transmission chains leading to new cases. Individual patients might benefit from early induction of
renoprotective treatment.
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Dipeptidyl-peptidase-4, Angiotensin-converting-enzyme-2Coronaviruses (CoVs) cause human disease with symptoms
ranging from mild respiratory symptoms to severe pneu-
monia [1]. In September 2012, a novel CoV termed the
Middle East Respiratory Syndrome (MERS)-CoV emerged
on the Arabian Peninsula with 163 laboratory-confirmed
cases including 71 deaths so far (World Health Organiza-
tion, December 2nd, http://www.who.int/csr/don/2013_12_* Correspondence: drosten@virology-bonn.de
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reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.02/en/index.html). Due to its distribution in several coun-
tries of the Arabian Peninsula there is a risk of global
spread through travel and pilgrimage, posing a potential
threat to global public health.
The clinical picture of MERS-CoV infection is character-
ized by acute atypical pneumonia and respiratory failure,
resembling symptoms caused by SARS-CoV [2-5]. Acute
renal failure (ARF) was described in a number of MERS
cases, with potential influence on disease severity [2,3,5-7].
ARF has neither been a typical feature of SARS, nor has it
been commonly observed in infections caused by any
other CoV, including human HCoV-NL63, -229E, –OC43,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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patients were reportred to have underlying medical condi-
tions such as diabetes, chronic cardiac disease and chronic
renal disease [4,8].
It has been shown recently that MERS-CoV enters tar-
get cells not via the SARS-CoV receptor Angiotensin-
converting-enzyme-2 (ACE-2), but via binding to
Dipeptidyl-peptidase 4 (DPP-4) [9,10]. Both, ACE-2 and
DPP-4 are expressed in several human tissues, including
the kidney [11,12]. However, kidney infection has not
been compared between MERS-CoV and SARS-CoV,
and no post-mortem investigations on patients who suc-
cumbed to MERS-CoV have been done. To assess the
potential role of kidney affection in MERS-CoV infection,
we reviewed all peer-reviewed or communicated reports
on MERS cases for information on kidney involvement.
The search was performed in PubMed and Promed.Mail
(http://www.promedmail.org) using the search term “cor-
onavirus” on items published between 15th September
2012 and 16th September 2013. The broad search term
was chosen due to inconsistencies of nomenclature before
the consensus name MERS-CoV was announced [13].
In total, the search revealed 655 publications, includ-
ing 508 articles in PubMed, and 147 reports in ProMed
(Figure 1). All identified publications were reviewed inFigure 1 Flowchart of study selection. Systematic search strategies were
MERS-CoV infection. Data sources used were Pubmed (www.ncbi.nlm.nih.g
searching the term “coronavirus” with a date range from 15th September 2
identified publications were reviewed for clinical data on kidney function (i
patient sex and age, country of patient origin and travel route, onset of illn
on which ARF occurred, as well as clinical outcome (death or survival) were
a total of 12 MERS-CoV patients and their kidney function during the coursorder to identify clinical descriptions of MERS-CoV in-
fection that included information on kidney function, ir-
respective of whether they were pointing to normal or
impaired function. In cases where two reports on the
same patient were available, only the report with the more
detailed clinical description was selected. From all identi-
fied reports, we extracted information on patient sex and
age, country of patient origin and travel route, onset of ill-
ness, presence or absence of ARF, date of onset of ARF,
day of illness on which ARF occurred, as well as clinical
outcome (death or survival). Among 21 publications de-
scribing a total of 111 MERS-CoV patients (double-
reporting of the same patients could not be excluded), a
total of 7 publications were identified that specifically ad-
dressed kidney function [2,3,5-7,14,15]. In these 7 publica-
tions, a total of 12 MERS patients were described with
disease onset dates ranging from April 2012 to March
2013 (Table 1). All patients were male with a mean age
of 47 years (range 25–73 years), originating from Jordan,
Saudi Arabia, and Qatar, including imported cases to the
United Kingdom (UK), Germany and France. Nine of those
12 patients (75%) developed ARF during the acute course
of MERS-CoV infection. For 6 of those 9 patients, dates of
onset of ARF were available, suggesting a median time
of 11 days (SD ±2,0 days) from first symptoms to onset ofapplied to identify all reports on patients’ kidney function during
ov/pubmed/) and Promed.Mail (http://www.promedmail.org) by
012 (date of the first MERS-CoV report) to 16th September 2013. All
rrespective of pointing to normal or impaired function). Data on
ess, presence or absence of ARF, date of onset of ARF, day of illness
extracted. In total, 7 publications were finally included that described
e of disease.
Table 1 MERS-CoV patients with explicit reports on presence or absence of acute renal failure (ARF)
Nr. Patient Country Onset of illness ARF Onset ARF ARF on day of illness Outcome Reference
1 25 y m Jordan Apr 12, day nd Yes nd nd Fatal [7]
2 60 y m Saudi Arabia 7 Jun 12 Yes 16 Jun 12 10 Fatal [2]
3 49 y m UK ex Qatar 3 Sep 12 Yes 14 Sep 12 12 Fatal [15]
4 45 y m Saudi Arabia Nov 12, day nd Yes nd nd Recovered [7]
5 45 y m Germany ex Qatar 5 Oct 12 Yes nd nd Recovered [14]
6 70 y m Saudi Arabia 5 Oct 12 Yes 16 Oct 12 12 Fatal [3]
7 39 y m Saudi Arabia 24 Oct 12 No - Fatal [3]
8 16 y m Saudi Arabia 3 Nov 12 No - Recovered [3]
9 31 y m Saudi Arabia 4 Nov 12 No - Recovered [3]
10 64 y m France ex Saudi Arabia 22 Apr 13 Yes 30 Apr 13 9 Fatal [6]
11 51 y m France 8 May 13 Yes 14 May 13 7 Recovered [6]
12 73 y m Germany ex Saudi Arabia 8 Mar 13 Yes 22 Mar 13 12 Fatal [5]
y – years of age; m - male; nd - no data available.
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while one of three patients without ARF died. However,
the differences found for the fatality rates in cases with and
without ARF during MERS-CoV infection were not statis-
tically significant.
To investigate a laboratory surrogate for susceptibility of
the kidney to MERS-CoV in comparison to SARS-CoV, we
analyzed cryoslides of a healthy human kidney for ACE-2
and DPP-4 expression by immunofluorescence. Staining
using polyclonal goat-anti-human ACE-2 immunoglobulin
(R&D systems) and polyclonal goat-anti-human DPP-4 im-
munoglobulin (R&D systems) showed that both receptors
are abundantly expressed in the healthy human kidney,
and both receptors are predominantly found in the epithe-
lial layer of the renal ducts (Figure 2A), as well as in human
primary epithelial cells derived from these ducts and in epi-
thelial cells from the human airway tract (Figure 2B).
To test whether kidney epithelial cells can actually be
infected in-vitro, we performed comparative infection
experiments with MERS- and SARS-CoV, using defined
cultures of primary kidney epithelial cells (HREpC, Promo-
cell, Heidelberg). As the bronchoalveolar epithelium of the
lung constitutes the primary target compartment for both
viruses, infection of human primary bronchial epithelial
cells (HBEpC, Promocell, Heidelberg) was studied in paral-
lel. As summarized in Figure 2, primary cells up to passage
4 were seeded at densities of 4x105/mL and inoculated
with either MERS-CoV strain EMC/2012, or SARS-CoV
strain Frankfurt-1 at multiplicities of infection (MOI) of
0.5 for 1 hour. Cells were washed twice and supernatants
were harvested immediately after washing, as well as 20
and 40 hours later. Cells were checked regularly for appear-
ance of cytopathic effects (CPE) by light microscopy. Rep-
lication of both viruses was quantified by titration of
supernatants in duplicate plaque assays on Vero cells as de-
scribed previously, as well as by real-time RT-PCR [9,16].Pronounced CPE consisting of visible and strong cell
lysis occurred only in HREpC, and only upon infection
with MERS-CoV (Figure 2C). Neither in HBEpCs upon
MERS-CoV infection, nor in HBEpCs or HREpCs upon
SARS-CoV infection any CPE was observed. Virus replica-
tion was nevertheless detectable by real time RT-PCR in all
experiments, confirming successful infection (Figure 1D).
The CPE in HREpCs consisted of rounding and detach-
ment of cells, leading to cell death in the majority of cells
already after 20 hours. Comparative quantification of infec-
tious virus production between SARS- and MERS-CoV
showed that MERS-CoV replicates to high titers in HREpC
with almost 1000-fold higher concentrations of infectious
MERS-CoV progeny than in HBEpCs. In SARS-CoV infec-
tion, only a small difference between primary kidney and
bronchial epithelial cells was seen (Figure 1E).
Our results from in-vitro infection experiments sug-
gest differences in kidney cell involvement might exist
between SARS- and MERS-CoV infection. In a retrospect-
ive analysis of 536 SARS cases, only in 36 (6.7%) patients
acute renal impairment was diagnosed. ARF occurred ra-
ther late in the course of disease after a median of 20 days
from the appearance of first symptoms [17]. In our litera-
ture review of MERS cases, ARF occurred much earlier,
namely in 6 of 9 sufficiently-described patients after a me-
dian of 11 days. To date, it is difficult to compare these
clinical data with experiences from animal models. The
only animal that exhibits clinical signs similar to human
MERS-CoV infection is the rhesus macaque, but none of
the available studies reported kidney failure in macaques
[18-20]. Only very small amounts of viral RNA were de-
tected in kidney tissue, and none in urine. Macaques
might be of limited value for the study of MERS-CoV-
specific kidney pathology as seen in humans.
While no autopsy data have become available for pa-
tients infected with MERS-CoV, post-mortem studies
Figure 2 SARS- and MERS-CoV receptor expression and virus infection experiments in human primary cells. (A) SARS- and MERS-CoV
receptor expression of human Angiotensin-converting-enzyme-2 (ACE-2) and Dipeptidyl-peptidase-4 (DPP-4), respectively, in cryosections of a
healthy human kidney and (B) in primary bronchial (HBEpC) and renal (HREpC) epithelial cells. For positive controls, ACE2- and DPP-4-expressing
primate cells (kidney cells from African green monkey [Vero E6]) were stained in parallel. Cell lines known to be negative for ACE-2 (kidney cells from
Syrian hamster [BHK]) or DPP-4 (kidney cells from African green monkey [COS-7]) were used as negative controls. The white bar represents 50 μm.
(C) Cell morphology and cytopathic effect (CPE) formation of human primary renal epithelial cells (HREpC) infected with MERS-CoV or SARS-CoV
with 0.5 plaque-forming units of either virus per cell. A pronounced CPE formation 20 hours post infection (hpi) was seen only after infection with
MERS-CoV in HREpC but not in cells infected with SARS-CoV. No CPE formation was seen in HBEpC infected with MERS-CoV or SARS-CoV (data not
shown). Upper row: 100-fold magnification, lower row: 400-fold magnification, bright field microscopy (D) Replication of SARS- and MERS-CoV on
HBEpC and HREpC determined by real time RT-PCR after 0, 20 and 40 hpi (E) Progeny virus measured by titration of supernatants in duplicates in a
plaque assay in Vero cells. MERS-CoV replicates in HREpC with peak titers of 6.2 log plaque forming units (PFU)/mL, showing a 2,9-fold log difference
between HREpC and HBEpC, while replication of SARS-CoV showed only a 1-fold log difference between bronchial and renal primary cells. Replication
levels for each virus used are given as log of the genome equivalents (GEs) (D) or as plaque-forming units (PFUs) (E). All virus infection experiments
were performed in triplicates. Bars represent mean values, error bars represent standard deviation of triplicates.
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pathological findings revealed mainly acute tubular ne-
crosis without evidence of glomerular pathology, which
is considered to be a consequence of systemic inflamma-
tory response in the context of multi-organ failure, ra-
ther than a specific effect of viral infection of the kidney
[17]. SARS-CoV has never been successfully isolated
from post mortem kidney tissue of infected patients [21].
In-vitro studies of SARS-CoV with immortalized human
proximal tubular epithelial cells showed replication with-
out cell impairment as seen in our study, while no infec-
tion of podocyte cell lines and only low-level replication
in glomerular mesangial cells (MC) was seen, providing
further evidence against specific involvement of the renal
tract in SARS-CoV infection [22]. In contrast, MERS-CoV
was shown to efficiently replicate in a broad range of bat,
primate and also human kidney epithelial cell lines thatare commonly used as laboratory models [9]. The abun-
dant expression of both viruses’ entry receptors in kidney
epithelium argues against receptor-dependent limitations
to viral kidney tropism. Specific interference of MERS-
CoV with the induction of the interferon response pro-
vides one of many possible explanations for an increased
capacity of MERS-CoV to replicate in kidney cells [23].
The clear differences in viral permissiveness of primary
kidney epithelial cells suggest these cells to be appropriate
models for the identification of host-specific restriction
factors in the future. We are aware that cell culture resem-
bles a limited model of viral infection which will not re-
flect the complexity of infection in-vivo. Nevertheless, our
results have some congruence with clinical observations
in a well-investigated MERS case [5]. Virus in the urine
has been detected as late as day 12 of illness, albeit at low
concentrations. Virus was detected in the urine but not in
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tion in the kidneys. Of note, by using a model to assess
the ability of CoVs to persist in the environment, it was
shown that MERS-CoV has similarities to viruses that are
transmitted via the fecal-oral route [24]. The authors sug-
gest that this could hint for oral-urine transmission of
MERS-CoV. Further data on virus shedding in the urine
over the course of disease are urgently needed. If the kid-
ney should indeed constitute a site of primary virus repli-
cation, shedding of virus in the urine might provide a
possible source for human-to-human transmission, espe-
cially in health-care settings or among close family contacts
[3,6,7]. Clinical guidelines should consider the possibility
that MERS patients may benefit from early induction of
renoprotective treatment.
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